» Articles » PMID: 1373488

Targeted Cleavage of MRNA in Vitro by RNase P from Escherichia Coli

Overview
Specialty Science
Date 1992 Apr 15
PMID 1373488
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

External guide sequences (EGSs) complementary to mRNAs that encode beta-galactosidase from Escherichia coli and nuclease A from Staphylococcus aureus can target these RNAs for cleavage in vitro by RNase P from E. coli. Specific cleavage occurs at locations predicted by the nucleotide sequences of the EGSs. EGSs with regions complementary to the mRNAs that are as short as 13 nucleotides function efficiently and turn over slowly during incubation with the target substrate and the enzyme. EGSs composed of deoxyribonucleotides as well as those composed of ribonucleotides are effective, but cleavage of the targeted substrate with DNA as an EGS is about 10-fold less efficient than that with RNA as an EGS. An RNA EGS inhibited the formation of beta-galactosidase activity in a crude extract (S30) of E. coli that was capable of catalyzing coupled transcription-translation reactions.

Citing Articles

Engineering of RNase P Ribozymes for Therapy against Human Cytomegalovirus Infection.

Smith A, Zhang I, Trang P, Liu F Viruses. 2024; 16(8).

PMID: 39205170 PMC: 11360822. DOI: 10.3390/v16081196.


Assessment of configurations and chemistries of bridged nucleic acids-containing oligomers as external guide sequences: a methodology for inhibition of expression of antibiotic resistance genes.

Jackson A, Jani S, Sala C, Soler-Bistue A, Zorreguieta A, Tolmasky M Biol Methods Protoc. 2016; 1(1).

PMID: 27857983 PMC: 5108630. DOI: 10.1093/biomethods/bpw001.


RNase P-Mediated Sequence-Specific Cleavage of RNA by Engineered External Guide Sequences.

Derksen M, Mertens V, Pruijn G Biomolecules. 2015; 5(4):3029-50.

PMID: 26569326 PMC: 4693268. DOI: 10.3390/biom5043029.


External guide sequence technology: a path to development of novel antimicrobial therapeutics.

Davies-Sala C, Soler-Bistue A, Bonomo R, Zorreguieta A, Tolmasky M Ann N Y Acad Sci. 2015; 1354:98-110.

PMID: 25866265 PMC: 4600001. DOI: 10.1111/nyas.12755.


(Non-)translational medicine: targeting bacterial RNA.

Dinan A, Loftus B Front Genet. 2013; 4:230.

PMID: 24265632 PMC: 3821060. DOI: 10.3389/fgene.2013.00230.


References
1.
Baer M, Altman S . A catalytic RNA and its gene from Salmonella typhimurium. Science. 1985; 228(4702):999-1002. DOI: 10.1126/science.2408335. View

2.
Baer M, Arnez J, Vioque A, Altman S . Preparation and characterization of RNase P from Escherichia coli. Methods Enzymol. 1990; 181:569-82. DOI: 10.1016/0076-6879(90)81152-k. View

3.
McClain W, Altman S . Model substrates for an RNA enzyme. Science. 1987; 238(4826):527-30. DOI: 10.1126/science.2443980. View

4.
Vioque A, Arnez J, Altman S . Protein-RNA interactions in the RNase P holoenzyme from Escherichia coli. J Mol Biol. 1988; 202(4):835-48. DOI: 10.1016/0022-2836(88)90562-1. View

5.
Bartkiewicz M, Gold H, Altman S . Identification and characterization of an RNA molecule that copurifies with RNase P activity from HeLa cells. Genes Dev. 1989; 3(4):488-99. DOI: 10.1101/gad.3.4.488. View